Key facts
- Boston Medical Sciences’s last known valuation is $31.0M.
- It has raised $9.2M; the latest was Early Stage VC ($6.5M) in Oct 2024.
- Notable investors include Mitsubishi UFJ Capital, Global Brain, JIC Venture Growth Investments, Beyond Next Ventures, Meiji Yasuda Life Insurance Company — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Boston Medical Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Boston Medical Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Boston Medical Sciences
Developer of a non-invasive colorectal cancer detection platform designed to improve patient outcomes by leveraging data for decision-making. The company's platform utilizes artificial intelligence to perform virtual bowel cleansing, which helps prepare the colon for examination without the traditional discomfort associated with laxatives, enabling healthcare providers with enhanced detection and treatment through technology.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2023
- Website
- b-ms.tech/
- Ownership
- Privately Held (backing)
Boston Medical Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Boston Medical Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Boston Medical Sciences in its N-PORT filings yet. We sweep new filings monthly.